M J Boucher1, J Morisset, P H Vachon, J C Reed, J Lainé, N Rivard. 1. Groupe du Conseil de Recherches Médicales sur le Développement Fonctionnel et la Physiopathologie du Tube Digestif, Département d'Anatomie et Biologie Cellulaire, Université de Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada.
Abstract
BACKGROUND AND AIMS: Growth factors are well known for their participation in the regulation of cell proliferation and survival. However, the intracellular signaling pathways by which growth factors promote survival are still poorly understood. In the present study, using the MIA PaCa-2 cell line, a well-established model of pancreatic cancer cells, we analyzed the roles of ERK1/2 activities in the regulation of cell survival and investigated some of the mechanisms involved. METHODS: The ability of the MEK inhibitor PD98059 to modulate survival of the MIA PaCa-2 cells was evaluated, and the responses were correlated with expression of Bcl-2 homologs and caspases 1, 3, 6, 8, and 9 activities. RESULTS: Herein, we showed that inhibition of ERK1/2 activities caused (1) a G1 arrest; (2) a down-regulation of the expression levels of the anti-apoptotic homologs Bcl-2, Mcl-1, and Bcl-X(L) without affecting the pro-apoptotic levels of Bax and Bak; (3) a promotion of caspases 3, 6, 8, and 9 activities; (4) a stimulation of PARP cleavage; and (5) a programmed cell death by apoptosis. CONCLUSION: Our data suggest that activation of the ERK pathway functions to protect pancreatic tumor cells from apoptosis as well as to regulate their progression in the cell cycle. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND AND AIMS: Growth factors are well known for their participation in the regulation of cell proliferation and survival. However, the intracellular signaling pathways by which growth factors promote survival are still poorly understood. In the present study, using the MIA PaCa-2 cell line, a well-established model of pancreatic cancer cells, we analyzed the roles of ERK1/2 activities in the regulation of cell survival and investigated some of the mechanisms involved. METHODS: The ability of the MEK inhibitor PD98059 to modulate survival of the MIA PaCa-2 cells was evaluated, and the responses were correlated with expression of Bcl-2 homologs and caspases 1, 3, 6, 8, and 9 activities. RESULTS: Herein, we showed that inhibition of ERK1/2 activities caused (1) a G1 arrest; (2) a down-regulation of the expression levels of the anti-apoptotic homologs Bcl-2, Mcl-1, and Bcl-X(L) without affecting the pro-apoptotic levels of Bax and Bak; (3) a promotion of caspases 3, 6, 8, and 9 activities; (4) a stimulation of PARP cleavage; and (5) a programmed cell death by apoptosis. CONCLUSION: Our data suggest that activation of the ERK pathway functions to protect pancreatic tumor cells from apoptosis as well as to regulate their progression in the cell cycle. Copyright 2000 Wiley-Liss, Inc.
Authors: Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad Journal: Expert Opin Ther Targets Date: 2010-06 Impact factor: 6.902
Authors: Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant Journal: Leuk Res Date: 2010-02-01 Impact factor: 3.156
Authors: Alisan Kahraman; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Fernando J Barreyro; Maria E Guicciardi; Yuko Akazawa; Karen Braley; Ruth W Craig; Gregory J Gores Journal: Dig Dis Sci Date: 2008-12-03 Impact factor: 3.199
Authors: Wei-Bin Zheng; Yang-Jia Li; Yang Wang; Jie Yang; Can-Can Zheng; Xiao-Hui Huang; Bin Li; Qing-Yu He Journal: Am J Cancer Res Date: 2017-11-01 Impact factor: 6.166